| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natural Killer T-Cells | 16 | 2022 | 54 | 6.900 |
Why?
|
| B-Lymphocytes | 17 | 2024 | 276 | 4.960 |
Why?
|
| Antigens, CD1d | 18 | 2017 | 45 | 3.800 |
Why?
|
| Bacterial Toxins | 10 | 2024 | 265 | 3.670 |
Why?
|
| Clostridium Infections | 7 | 2024 | 66 | 3.650 |
Why?
|
| Immunoglobulin G | 13 | 2024 | 266 | 3.540 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 6 | 2020 | 34 | 2.560 |
Why?
|
| Immunologic Memory | 7 | 2024 | 58 | 2.420 |
Why?
|
| Immunity, Humoral | 7 | 2020 | 46 | 2.410 |
Why?
|
| Galactosylceramides | 12 | 2021 | 31 | 2.340 |
Why?
|
| Bacterial Proteins | 5 | 2024 | 474 | 2.120 |
Why?
|
| Immunization | 11 | 2022 | 118 | 1.960 |
Why?
|
| Antigens, CD1 | 7 | 2017 | 15 | 1.940 |
Why?
|
| Antibodies, Neutralizing | 6 | 2021 | 69 | 1.930 |
Why?
|
| Antigens, Bacterial | 5 | 2021 | 159 | 1.840 |
Why?
|
| Lymphocyte Activation | 10 | 2022 | 205 | 1.750 |
Why?
|
| Plasma Cells | 4 | 2019 | 21 | 1.640 |
Why?
|
| Animals | 42 | 2024 | 10073 | 1.550 |
Why?
|
| Mice | 32 | 2024 | 4470 | 1.530 |
Why?
|
| Bacterial Vaccines | 3 | 2022 | 28 | 1.510 |
Why?
|
| Antibodies | 5 | 2013 | 124 | 1.470 |
Why?
|
| Mice, Inbred C57BL | 20 | 2024 | 1496 | 1.420 |
Why?
|
| Killer Cells, Natural | 7 | 2014 | 60 | 1.410 |
Why?
|
| Germinal Center | 2 | 2024 | 20 | 1.400 |
Why?
|
| Receptors, Fc | 4 | 2021 | 30 | 1.250 |
Why?
|
| Antigens | 3 | 2019 | 66 | 1.200 |
Why?
|
| Alum Compounds | 2 | 2022 | 6 | 1.190 |
Why?
|
| Antibody Formation | 6 | 2024 | 75 | 1.120 |
Why?
|
| Adjuvants, Immunologic | 5 | 2022 | 63 | 1.100 |
Why?
|
| Antigen Presentation | 6 | 2022 | 78 | 1.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2024 | 27 | 0.910 |
Why?
|
| Bacillus anthracis | 3 | 2015 | 146 | 0.830 |
Why?
|
| Glycolipids | 4 | 2011 | 18 | 0.820 |
Why?
|
| Anthrax Vaccines | 2 | 2015 | 34 | 0.820 |
Why?
|
| Cell Differentiation | 4 | 2019 | 398 | 0.800 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2021 | 64 | 0.780 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2021 | 13 | 0.760 |
Why?
|
| Digestive System | 1 | 2021 | 16 | 0.750 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 72 | 0.720 |
Why?
|
| Female | 21 | 2024 | 14613 | 0.720 |
Why?
|
| T-Lymphocytes | 5 | 2016 | 278 | 0.720 |
Why?
|
| Intestinal Diseases | 1 | 2020 | 11 | 0.710 |
Why?
|
| Antitoxins | 2 | 2021 | 13 | 0.690 |
Why?
|
| Bacterial Infections | 1 | 2020 | 54 | 0.690 |
Why?
|
| Antigen-Presenting Cells | 2 | 2012 | 31 | 0.650 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2019 | 9 | 0.640 |
Why?
|
| Mice, Knockout | 9 | 2017 | 794 | 0.640 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2019 | 30 | 0.630 |
Why?
|
| Polysaccharides | 1 | 2019 | 60 | 0.620 |
Why?
|
| Anthrax | 2 | 2015 | 85 | 0.540 |
Why?
|
| Antibodies, Bacterial | 3 | 2021 | 100 | 0.540 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2013 | 7 | 0.520 |
Why?
|
| Interleukin-4 | 2 | 2016 | 23 | 0.520 |
Why?
|
| Cardiotoxicity | 1 | 2015 | 4 | 0.500 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 23 | 0.490 |
Why?
|
| CD40 Ligand | 2 | 2011 | 13 | 0.480 |
Why?
|
| Cricetulus | 4 | 2020 | 56 | 0.480 |
Why?
|
| CHO Cells | 4 | 2020 | 96 | 0.480 |
Why?
|
| Humans | 21 | 2024 | 27067 | 0.460 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2013 | 1 | 0.440 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 8 | 0.440 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2017 | 45 | 0.430 |
Why?
|
| Antigens, Ly | 1 | 2013 | 9 | 0.430 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 6 | 0.430 |
Why?
|
| B-Cell Activating Factor | 1 | 2013 | 31 | 0.430 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2010 | 58 | 0.420 |
Why?
|
| Interferon-gamma | 2 | 2014 | 103 | 0.390 |
Why?
|
| Proteins | 1 | 2014 | 245 | 0.390 |
Why?
|
| Lymphocytes, Null | 1 | 2011 | 1 | 0.390 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 162 | 0.380 |
Why?
|
| Antigens, CD | 3 | 2007 | 134 | 0.380 |
Why?
|
| Dendritic Cells | 1 | 2012 | 142 | 0.350 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 75 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 317 | 0.320 |
Why?
|
| Endosomes | 2 | 2006 | 44 | 0.310 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2012 | 253 | 0.300 |
Why?
|
| Vaccination | 3 | 2021 | 174 | 0.300 |
Why?
|
| Cell Line | 5 | 2015 | 681 | 0.280 |
Why?
|
| Ligands | 2 | 2022 | 168 | 0.260 |
Why?
|
| Tuberculosis | 1 | 2006 | 23 | 0.260 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2006 | 28 | 0.250 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2005 | 95 | 0.250 |
Why?
|
| Cells, Cultured | 4 | 2012 | 976 | 0.250 |
Why?
|
| Adaptive Immunity | 2 | 2017 | 37 | 0.250 |
Why?
|
| Biotin | 1 | 2005 | 25 | 0.250 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2005 | 33 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 153 | 0.240 |
Why?
|
| Cell Communication | 2 | 2019 | 66 | 0.240 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 74 | 0.240 |
Why?
|
| Immunoglobulin A | 2 | 2020 | 22 | 0.240 |
Why?
|
| Neoplasms | 1 | 2013 | 765 | 0.230 |
Why?
|
| Cytokines | 3 | 2012 | 439 | 0.230 |
Why?
|
| Chemokine CXCL12 | 1 | 2024 | 9 | 0.230 |
Why?
|
| Flow Cytometry | 3 | 2012 | 285 | 0.230 |
Why?
|
| Adoptive Transfer | 3 | 2015 | 25 | 0.230 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 1405 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2015 | 20 | 0.210 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2002 | 5 | 0.200 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 42 | 0.200 |
Why?
|
| Th2 Cells | 2 | 2012 | 14 | 0.200 |
Why?
|
| Survival Analysis | 2 | 2015 | 278 | 0.200 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2022 | 13 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 48 | 0.190 |
Why?
|
| Cysts | 1 | 2022 | 21 | 0.190 |
Why?
|
| Immunophenotyping | 1 | 2022 | 59 | 0.190 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2022 | 26 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 515 | 0.190 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2022 | 48 | 0.190 |
Why?
|
| Interferons | 1 | 2022 | 68 | 0.190 |
Why?
|
| Enterotoxins | 1 | 2021 | 21 | 0.190 |
Why?
|
| Immunity | 1 | 2021 | 26 | 0.190 |
Why?
|
| Macrophages | 2 | 2017 | 279 | 0.190 |
Why?
|
| Influenza, Human | 1 | 2022 | 84 | 0.190 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2013 | 26 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2022 | 138 | 0.170 |
Why?
|
| Mucous Membrane | 1 | 2020 | 26 | 0.170 |
Why?
|
| Signal Transduction | 5 | 2017 | 1377 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 489 | 0.160 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 3 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2019 | 114 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 32 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2020 | 705 | 0.150 |
Why?
|
| Biomarkers | 1 | 2022 | 738 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 105 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 89 | 0.150 |
Why?
|
| Interleukins | 2 | 2016 | 111 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2018 | 40 | 0.150 |
Why?
|
| Bacteria | 1 | 2020 | 264 | 0.150 |
Why?
|
| Male | 4 | 2021 | 13003 | 0.150 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 44 | 0.140 |
Why?
|
| Protein Transport | 3 | 2006 | 153 | 0.140 |
Why?
|
| Cross-Priming | 1 | 2016 | 5 | 0.140 |
Why?
|
| Haptens | 1 | 2016 | 8 | 0.140 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 31 | 0.130 |
Why?
|
| Cricetinae | 1 | 2016 | 129 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.130 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 25 | 0.120 |
Why?
|
| Troponin I | 1 | 2015 | 14 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 1936 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 79 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2017 | 774 | 0.120 |
Why?
|
| Receptors, CXCR5 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2015 | 2 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 283 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2015 | 37 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 239 | 0.120 |
Why?
|
| Receptors, Interleukin | 1 | 2014 | 12 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2014 | 76 | 0.110 |
Why?
|
| Transplantation Chimera | 1 | 2013 | 4 | 0.110 |
Why?
|
| Aluminum Hydroxide | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hemocyanins | 1 | 2013 | 7 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 11 | 0.110 |
Why?
|
| Intestines | 1 | 2014 | 117 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 80 | 0.110 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 165 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 408 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 445 | 0.100 |
Why?
|
| Adult | 2 | 2022 | 7476 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2012 | 76 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 481 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2006 | 264 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2013 | 212 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 156 | 0.090 |
Why?
|
| Aged | 1 | 2020 | 5212 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 11 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2012 | 506 | 0.090 |
Why?
|
| Neutralization Tests | 1 | 2010 | 32 | 0.090 |
Why?
|
| Toxoplasma | 1 | 2010 | 33 | 0.080 |
Why?
|
| Receptors, Peptide | 1 | 2009 | 20 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 102 | 0.080 |
Why?
|
| Middle Aged | 1 | 2020 | 6882 | 0.080 |
Why?
|
| Titrimetry | 1 | 2008 | 6 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2008 | 35 | 0.080 |
Why?
|
| Toll-Like Receptors | 1 | 2008 | 22 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2007 | 13 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 195 | 0.070 |
Why?
|
| GTP Phosphohydrolases | 1 | 2007 | 18 | 0.070 |
Why?
|
| STAT5 Transcription Factor | 1 | 2007 | 6 | 0.070 |
Why?
|
| Urothelium | 1 | 2007 | 35 | 0.070 |
Why?
|
| Thymus Gland | 1 | 2007 | 53 | 0.070 |
Why?
|
| HLA Antigens | 1 | 2007 | 61 | 0.070 |
Why?
|
| Spleen | 1 | 2007 | 109 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2007 | 38 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2007 | 118 | 0.070 |
Why?
|
| Cell Degranulation | 1 | 2006 | 5 | 0.070 |
Why?
|
| Ovalbumin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Eosinophils | 1 | 2006 | 6 | 0.070 |
Why?
|
| Retina | 1 | 2010 | 422 | 0.070 |
Why?
|
| Immunoglobulin E | 1 | 2006 | 18 | 0.070 |
Why?
|
| NADPH Oxidases | 1 | 2006 | 69 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2006 | 67 | 0.070 |
Why?
|
| Syk Kinase | 1 | 2005 | 12 | 0.060 |
Why?
|
| Enzyme Precursors | 1 | 2005 | 16 | 0.060 |
Why?
|
| Peptides | 2 | 2022 | 280 | 0.060 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 10 | 0.060 |
Why?
|
| Stilbenes | 1 | 2005 | 90 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2004 | 33 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2004 | 72 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 110 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2007 | 467 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2004 | 123 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2004 | 236 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 278 | 0.050 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2022 | 9 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cilia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 46 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 264 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 74 | 0.050 |
Why?
|
| Biological Products | 1 | 2022 | 60 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 247 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2002 | 567 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 205 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 276 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2019 | 65 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 69 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 51 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 206 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2019 | 253 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 846 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1219 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 108 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 818 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 54 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 1148 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 290 | 0.040 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2017 | 6 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2017 | 10 | 0.040 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2017 | 12 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 12 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2017 | 16 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 251 | 0.040 |
Why?
|
| Cell Survival | 1 | 2018 | 395 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 138 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 457 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 666 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1267 | 0.030 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 655 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 90 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1570 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2010 | 11 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2010 | 35 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2010 | 49 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 68 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 608 | 0.020 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2010 | 62 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 143 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2007 | 8 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 2007 | 14 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 46 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 28 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2007 | 9 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2007 | 28 | 0.020 |
Why?
|
| Transgenes | 1 | 2007 | 59 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 92 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 114 | 0.020 |
Why?
|
| Respiratory Burst | 1 | 2006 | 10 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2007 | 648 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 440 | 0.020 |
Why?
|
| Neutrophils | 1 | 2006 | 179 | 0.020 |
Why?
|
| Lysosome-Associated Membrane Glycoproteins | 1 | 2004 | 1 | 0.010 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2004 | 2 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 9 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2004 | 6 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2004 | 17 | 0.010 |
Why?
|
| Transport Vesicles | 1 | 2004 | 8 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 86 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2004 | 36 | 0.010 |
Why?
|
| Endocytosis | 1 | 2004 | 81 | 0.010 |
Why?
|